

Curriculum vitae Alberto Bardelli

Personal details

Born in 1967

Nationality: Italian

Email: alberto.bardelli@unito.it

Website:

ORCID ID: 0000-0003-1647-5070; Scopus ID: 7006937523; Researcher ID: J-9721-2018

Educations

1991-1996 PhD degree in Biochemistry and Molecular Biology, University College London. Supervisor: Prof. M. Waterfield

1991 Master Degree in Biological Sciences, University of Torino, Italy, 110/110 cum laude.

Professional experiences and current position

2022-pres. Scientific Director, IFOM ETS – The AIRC Institute of Molecular Oncology

2016-pres. Full Professor, University of Torino, School of Medicine.

2004-2022 Group Leader, Candiolo Cancer Institute IRCCS, Candiolo (To), Italy

1999-2004 Postdoctoral fellow, The Johns Hopkins University; Baltimore MD USA. Supervisor: Prof. Bert Vogelstein.

1996-1999 Postdoctoral Fellow, IRCC and the University of Torino, School of Medicine

Participation to Directive Boards of Scientific Societies and/or Institutions:

2022 TEFAF Oncology Chair and Visiting Professor in Oncology at the Faculty of Health, Medicine and Life Sciences / GROW school of Oncology and Reproduction, Maastricht (NL)

2021-pres. Scientific Advisory Board member, Onco Institute, Utrecht (The Netherlands)

2019-pres. The Johns Hopkins Society of Scholars, Baltimore (USA)

2018-pres. Scientific Advisory Board member, MD Anderson Moon Shots Program, Houston (USA)

2018-pres. Scientific Advisory Board member, Neophore, Cambridge (UK)

2015-pres. Board Member, European Association for Cancer Research (EACR)

2013-pres. Scientific Committee, Pezcoller Foundation

2013-pres. Scientific Committee, AIRC (Italian Association for Cancer Research)

2017-2021 Scientific Advisory Board member, Cancer Research UK Manchester Institute, Manchester (UK)

2018-2020 President, EACR (European Association for Cancer Research)

2008-2017 Scientific Advisory Board member, Horizon Discovery, Cambridge (UK)

Honors

2020 Guido Venosta Award, FIRC AIRC, Presidenza della Repubblica Italiana

2019 Member of the Johns Hopkins Society of Scholars

2018-2022 Highly Cited Researcher, Web of Science, Claryvate

2017 European Society for Medical Oncology (ESMO) Translational Research Award

2017 Fellow of European Molecular Biology Organization (EMBO)

2016 Grant for Oncology Innovation Research Project

2015 Fellow of the European Academy of Cancer Sciences

2015 Fellow of the Turin Academy of Sciences

2014 Thomson Reuters Highly Cited Researcher - Beautiful Minds List

2004 The Alfred Blalock Research Award - Johns Hopkins Medical School, Baltimore USA

1999-2004 Fellowship, Howard Hughes Medical Institute, Baltimore MD USA

1996 Cecilia Cioffrese -Cancer Research Award, Carlo Erba Foundation

1994 Francesca e Ferdinando Quartero, Cancer Research Prize, Italian Cancer Association

1994 VIII Mascia Brunelli-Award, Italian Cell Culture Association

1991 Graduated with Honor and Distinction (Laude, Menzione d'Onore), University of Torino

Teaching activity:

2016-pres. Full Professor, Histology, University of Turin, Italy

2006-2016 Associate Professor, Histology, University of Turin, Italy

1998-2005 Assistant Professor, Histology, University of Turin, Italy

Research main topics

Colorectal cancers. Drug resistance and tumor evolution. Immunogenomics. Mutation-specific pharmacogenomic profiling

Main projects as PI:

2021-2026 ERC Advanced Grant - European Research Council Executive Agency

2019-2024 IG2018 – Associazione Italiana per la Ricerca sul Cancro

2018-2025 Special Program 5 per mille metastases – Associazione Italiana per la Ricerca sul Cancro

Bibliometry (1991-present) (www.scopus.com)

H Index 95

Publications (selected)

1.	Di Nicolantonio F, Bardelli A Precision oncology for KRASG12C-mutant colorectal cancer. Nat Rev Clin Oncol. 2023 Mar 13. [Online ahead of print]
2.	Falcinelli M, Dell’Omo G, Grassi E, Mariella E, Leto SM, Scardellato S, Lorenzato A, Arena S, Bertotti A, Trusolino L, Bardelli A, d’Adda di Fagagna F. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT). Cell Death Dis. 2023 Feb 9;14(2):96.
3.	Torchiaro E, Petti C, Arena S, Sassi F, Migliardi G, Mellano A, Porporato R, Basiricò M, Gammaitoni L, Berrino E, Montone M, Corti G, Crisafulli G, Marchiò C, Bardelli A, Medico E. Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient. Front Oncol. 2023 Feb 2;13:1130852.
4.	Berrino E, Aquilano MC, Valtorta E, Amodio V, Germano G, Gusmini M, Gizzi K, Fenocchio E, Sapino A, Marsoni S, Sartore-Bianchi A, Bardelli A, Siena S, Bonoldi E, Marchiò C. Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. Mod Pathol. 2023 Feb;36(2):100012. Epub 2023 Jan 10.
5.	Amodio V, Lamba S, Chilà R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchiò C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell. 2023 Jan 9;41(1):196-209.
6.	Khawaja H, Briggs R, Latimer CH, Rassel M, Griffin D, Hanson L, Bardelli A, Di Nicolantonio F, McDade SS, Scott CJ, Lambe S, Maurya M, Lindner AU, Prehn JH, Sousa J, Winnington C, LaBonte MJ, Ross SJ, Van Schaeuybroeck S. Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. Mol Cancer Ther. 2023 Jan 3;22(1):135-149
7.	Flanagan DJ, Amirkhah R, Vincent DF, Gundaz N, Gentaz P, Cammareri P, McCooey AJ, McCorry AMB, Fisher NC, Davis HL, Ridgway RA, Lohuis J, Leach JDG, Jackstadt R, Gilroy K, Mariella E, Nixon C, Clark W, Hedley A, Markert EK, Strathdee D, Bartholin L, Redmond KL, Kerr EM, Longley DB, Ginty F, Cho S, Coleman HG, Loughrey MB, Bardelli A, Maughan TS, Campbell AD, Lawler M, Leedham SJ, Barry ST, Inman GJ, van Rheenen J, Dunne PD, Sansom OJ. Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nat Commun. 2022 Dec 7;13(1):7551.
8.	Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S, Sartore-Bianchi A. Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Front Oncol. 2022 Nov 7;12:1030232.
9.	Pergolizzi M, Bizzozero L, Maione F, Maldì E, Isella C, Macagno M, Mariella E, Bardelli A, Medico E, Marchiò C, Serini G, Di Nicolantonio F, Bussolino F, Arese M. The neuronal protein Neurologin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway. J Exp Clin Cancer Res. 2022 Sep 2;41(1):266.
10.	Durinkova E, Reilly NM, Buzo K, Mariella E, Chilà R, Lorenzato A, Dias JML, Grasso G, Pisati F, Lamba S, Corti G, Degasperi A, Cancelliere C, Mauri G, Andrei P, Linnebacher M, Marsoni S, Siena S, Sartore-Bianchi A, Nik-Zainal S, Di Nicolantonio F, Bardelli A*, Arena S* (* Shared last authorship) Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clin Cancer Res. 2022 Sep 1;28(17):3874-3889.

11.	Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldi E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D'Ambrosio L, Bardelli A , Pignochino Y, Grignani G. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. Front Oncol. 2022 Aug 30;12:844250.
12.	Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A . Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug;28(8):1612-1618.
13.	Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A . Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. Semin Cancer Biol. 2022 Sep;84:199-213.
14.	Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, Morano F, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Bardelli A . Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 2022 Jul 6;12(7):1656-1675.
15.	Russo M, Pompei S, Sogari A, Corigliano M, Crisafulli G, Puliafito A, Lamba S, Erriquez J, Bertotti A, Gherardi M, Di Nicolantonio F, Bardelli A , Cosentino Lagomarsino M. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nat Genet. 2022 Jul;54(7):976-984.
16.	Anagnostou V, Bardelli A , Chan TA, Turajlic S. The status of tumor mutational burden and immunotherapy. Nat Cancer. 2022 Jun;3(6):652-656.
17.	Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S, Siena S, Bardelli A . Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer. 2022 Aug;127(3):394-407
18.	Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss E, Govindan R, Tan I, Yap YS, Robinson WA, Morris C, Besse B, Bardelli A , Tie J, Kopetz S, Rosenfeld N Liquid biopsies for residual disease and recurrence Med. 2021 Dec 10; 2(12): 1292-1313
19.	Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A , de Braud F, Morano F, Cremolini C, Pietrantonio F. EGFR Amplification in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569
20.	Russo M, Sogari A & Bardelli A Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. Cancer Discov. 2021 Aug;11(8):1886-1895
21.	Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, and Bardelli A Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
22.	Picco G, Cattaneo C, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Sánchez Rodríguez I, Cancelliere C, Banerjee R, Schipper L, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, Yang F, Cell Model Network UK Group, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest E*, Bardelli A* , and Garnett MJ* (* Shared last authorship) Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. Cancer Discov. 2021 Aug;11(8):1923-1937.
23.	Invrea F, Punzi P, Petti C, Minelli R, Peoples MD, Bristow CA, Vurchio V, Corrado A, Bragoni A, Marchiò C, Bertotti A, Trusolino L, Bardelli A , Isella C, Carugo A, Draetta GF, and Medico E. Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways Cancers (Basel). 2021 Jul 28;13(15):3805
24.	Morello G, Cancila V, La Rosa M, Germano G, Lecis D, Amodio V, Zanardi F, Iannelli F, Greco D, La Paglia L, Fiannaca A, Urso AM, Graziano G, Ferrari F, Sangaletti S, Pupa SM, Chiodoni C, Pruneri G, Bardelli A , Colombo MP, Tripodo C. T cells expressing receptor recombination/revision machinery are detected in the tumor microenvironment and expanded in genomically over-unstable models. Cancer Immunol Res. 2021 Jul;9(7):825-837

25.	<p>Germano G, Lu S, Rospo G, Lamba S, Rousseau B, Fanelli S, Stenech D, Le DT, Hays J, Totaro MG, Amodio V, Chila R, Mondino A, Diaz LA, Di Nicolantonio F, Bardelli A. CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors. Cancer Discov. 2021 Jul;11(7):1844-1859.</p>
26.	<p>Fiorito V, Allocco AL, Petrillo S, Gazzano E, Torretta S, Marchi S, Destefanis F, Pacelli C, Audrito V, Provero P, Medico E, Chiabrando D, Porporato PE, Cancelliere C, Bardelli A, Trusolino L, Capitanio N, Deaglio S, Altruda F, Pinton P, Cardaci S, Riganti C, Tolosano E. The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. Cell Reports. 2021 Jun 15;35(11):109252.</p>
27.	<p>Bonnal RJP, Rossetti G, Lugli E, De Simone M, Guarini P, Brummelman J, Drufula L, Passaro M, Bason R, Gervasoni F, Della Chiara G, D'Oria C, Martinovic M, Curti S, Ranzani V, Cordiglieri C, Alvisi G, Mazza EMC, Oliveto S, Silvestri Y, Carelli E, Mazzara S, Bosotti R, Sarnicola ML, Godano C, Bevilacqua V, Lorenzo M, Siena S, Bonoldi E, Sartore-Bianchi A, Amatu A, Veronesi F, Novellis P, Alloisio M, Giani A, Zucchini N, Opocher E, Pisani Ceretti A, Mariani, Biffo S, Prati D, Bardelli A, Geginat J, Lanzavecchia A, Abrignani S, Pagani M Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors associate with disease progression Nat immunol. 2021 Jun;22(6):735-745</p>
28.	<p>Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A and Germano G Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers Cancers (Basel). 2021 May 27;13(11):2638</p>
29.	<p>Della Chiara G, Gervasoni F, Fakiola M, Godano C, D'Oria C, Azzolin L, Bonnal RJP, Moreni G, Drufula L, Rossetti G, Ranzani V, Bason R, De Simone M, Panariello F, Ferrari I, Fabbris T, Zanconato F, Forcato M, Romano O, Caroli J, Guarini P, Sarnicola ML, Cordenonsi M, Bardelli A, Zucchini N, Ceretti AP, Mariani NM, Cassingena A, Sartore-Bianchi A, Testa G, Gianotti L, Opocher E, Pisati F, Tripodo C, Macino G, Siena S, Bicciato S, Piccolo S, Pagani M. Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. Nat Commun. 2021 Apr 20;12(1):2340.</p>
30.	<p>Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discov. 2021 Jan;11(1):126-141</p>
31.	<p>Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev. 2020 Dec;91:102112.</p>
32.	<p>Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death Dis. 2020 Oct 29;11(10):930.</p>
33.	<p>Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, Ardizzoni A, Amatu A, Bencardino K, Valtorta E, Grassi E, Torri V, Bonoldi E, Sapino A, Vanzulli A, Regge D, Cappello G, Bardelli A, Trusolino L, Marsoni S, Siena S. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020 Sep;5(5):e000911.</p>
34.	<p>Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A. The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020 Sep;31(9):1135-1147.</p>
35.	<p>Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A*, Misale S* (* Shared last authorship) EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discov. 2020 Aug;10(8):1129-1139</p>
36.	<p>Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella C, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, Abrignani S, Siena S, Di Nicolantonio F, Bardelli A. A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. Clin Cancer Res. 2020 Mar 15;26(6):1372-1384</p>
37.	<p>Magri A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D'Incalci M, Zucchetti M, Di Nicolantonio F, Bardelli A. High-dose vitamin C enhances cancer immunotherapy. Sci Transl Med. 2020 Feb 26;12(532).</p>

38.	Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A , Scaltriti M, Drilon A, Iasonos A, Taylor BS, Hyman DM. TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin Cancer Res. 2020 Apr 1;26(7):1624-1632
39.	Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magri A, Novara L, Sarotto I, Nagel ZD, Piatt CG, Amatu A, Sartore-Bianchi A, Siena S, Bertotti A, Trusolino L, Corigliano M, Gherardi M, Cosentino Lagomarsino M, Di Nicolantonio F, Bardelli A Adaptive mutability of colorectal cancers in response to targeted therapies Science. 2019 Dec 20;366(6472):1473-1480
40.	Bertero L, Siravegna G, Rudà R, Soffietti R, Bardelli A , Cassoni P. Peering through a keyhole: Liquid biopsy in primary and metastatic central nervous system tumours. Neuropathol Appl Neurobiol. 2019 Dec;45(7):655-670
41.	Crisafulli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Barault L, Martinetti A, Morano F, Pietrantonio F, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A , Siravegna G. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open. 2019 Nov;4(6).
42.	Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, Garnett MJ, Bertotti A, Trusolino L, Di Nicolantonio F, Linnebacher M, Bardelli A *, Arena S* (* Shared last authorship) Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer. Clin Cancer Res. 2019 Oct 15;25(20):6243-6259
43.	Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A . How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct;30(10):1580-1590
44.	Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinnsson VA, Bardelli A , Parida L, Juric D, Getz G, Corcoran RB Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Sep;25(9):1415-1421
45.	Magri A, Bardelli A Does early metastatic seeding occur in colorectal cancer? Nat Rev Gastroenterol Hepatol. 2019 Aug 15.
46.	Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leshchiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A , Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019 Aug;9(8):1064-1079
47.	Lorenzato A, Magri A, Matafora V, Audrito V, Arcella P, Lazzari L, Montone M, Lamba S, Deaglio S, Siena S, Bertotti A, Trusolino L, Bachi A, Di Nicolantonio F, Bardelli A , Arena S. Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers (Basel). 2020 Mar 14;12(3).
48.	Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patanè DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A , Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Barault L. High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Front Oncol. 2019 Jul 12;9:622. eCollection 2019.
49.	Rospo G, Lorenzato A, Amirouchene-Angelozzi N, Magri A, Cancelliere C, Corti G, Negrino C, Amodio V, Montone M, Bartolini A, Barault L, Novara L, Isella C, Medico E, Bertotti A, Trusolino L, Germano G, Di Nicolantonio F, Bardelli A . Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Med. 2019 Jun 28;11(1):42
50.	Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A . Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019 May 15;25(10):3046-3053
51.	Reilly NM, Novara L, Di Nicolantonio F, Bardelli A . Exploiting DNA repair defects in colorectal cancer. Mol Oncol. 2019 Apr;13(4):681-700

52.	Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A , Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino M. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 Feb 1;25(3):989-999
53.	Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A , Siena S, Sartore-Bianchi A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev. 2019 Feb;73:41-53
54.	Siravegna G, Bardelli A . Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. Ann Oncol. 2019 Feb 1;30(2):157-159
55.	Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A , Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019 Feb;13(2):109-131
56.	Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A , Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019 Feb;30(2):211-218
57.	Germano G, Amirouchene-Angelozzi N, Rospo G and Bardelli A The clinical impact of the genomic landscape of mismatch repair deficient cancers Cancer Discov. 2018 Dec;8(12):1518-1528
58.	Ibarrola-Villava M, Cervantes A, Bardelli A Preclinical models for precision oncology. Biochim Biophys Acta. 2018 Dec;1870(2):239-246
59.	Truini A, Germano G, Bardelli A . Inactivation of DNA repair-prospects for boosting cancer immune surveillance. Genome Med. 2018 Nov 28;10(1):91.
60.	Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A , Sartore-Bianchi A, Di Nicolantonio F. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018 Nov;67(11):1995-2005
61.	Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A , Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol. 2018 Oct;19(10):1360-1371
62.	Knickelbein K, Tong J, Chen D, Wang YJ, Misale S, Bardelli A , Yu J, Zhang L. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene. 2018 Aug;37(33):4599-4610
63.	Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A , Villanueva A, Bernards R. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med. 2018 Jul;24(7):961-967
64.	Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer Cancer Cell. 2018 Jul 9;34(1):148-162
65.	Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nat Commun. 2018 Jun 12;9(1):2287
66.	Costanzo V, Bardelli A , Siena S, Abrignani S Exploring the links between cancer and placenta development. Open Biol. 2018 Jun;8(6). pii: 180081.

67.	Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A , Novara L, Wang L, Pupa S, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018 Jun 1;29(6):1394-1401
68.	Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A , Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108-1119
69.	Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A *, Tabernero J* (* Shared last authorship) Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Apr 12;4(4):e175245.
70.	Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A , Siena S, Ciardiello F. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018 Jan 10;3(1):e000299.
71.	Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer. Ann Oncol. 2018 Jan 1;29(1):119-126.
72.	Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, and Bardelli A Inactivation of DNA repair triggers neoantigen generation and im-pairs tumor growth Nature. 2017 Dec 7;552(7683):116-120
73.	Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A , Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2017 Dec 1;109(12)
74.	Siravegna G, Geuna E, Mussolin B, Crisafulli G, Bartolini A, Galizia D, Casorzo L, Sarotto I, Scaltriti M, Sapino A, Bardelli A , Montemurro F. Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open. 2017 Oct 9;2(4):e000253.
75.	Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A , Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Schaeybroeck SV; MERCuRIC consortium Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2017 Sep;14(9):562-576
76.	Siravegna G, Marsoni S, Siena S, Bardelli A Integrating liquid biopsies in the management of cancer Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
77.	Amirouchene-Angelozzi N, Swanton C, Bardelli A Tumor Evolution as a Therapeutic Target. Cancer Discov. 2017 Aug; 7(8):805-817.
78.	Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Ali G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A , Fontanini G, Tortora G, Melisi D. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients. Clin Cancer Res. 2017 Aug 1;23(15):4312-4322
79.	Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A , Pietrantonio F, Di Nicolantonio F. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br J Cancer. 2017 Jul 25;117(3):347-352

80.	Fuji T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp D, Piha-Paul S, Subbiah V, Tsimberidou AM, Huang H, Veronese S, Di Nicolantonio F, Pingle SC, Vibat CR, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz S, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A , Janku F Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15;23(14):3657-3666
81.	Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A , Counter CM, Wood KC. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat Commun. 2017 Jun 8;8:15617
82.	Rospo G, Corti G, Crisafulli G, Novara L, Bardelli A Tracking colorectal cancer evolution in time and space. Ann Oncol. 2017 Jun 1;28(6):1163-1165
83.	Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann Oncol. 2017 Jun 1;28(6):1302-1308
84.	Bardelli A Personalized test tracks cancer relapse Nature. 2017 May 24;545(7655):417-418
85.	Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Piccioni B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A , de Braud F. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017 May 15;23(10):2414-2422
86.	Picco G, Petti C, Centonze A, Torchiario E, Crisafulli G, Novara L, Acquaviva A, Bardelli A , Medico E Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO3 fusions EMBO Mol Med. 2017 Mar;9(3):293-303
87.	Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Graus Porta D, Tiedt R, Bardelli A , Juric D, Corcoran RB, Bardeesy N, Zhu AX Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 Mar;7(3):252-263
88.	Picco G, Petti C, Sassi F, Grillone K, Migliardi G, Rossi T, Isella C, Di Nicolantonio F, Sarotto I, Sapino A, Bardelli A , Trusolino L, Bertotti A, Medico E Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. J Natl Cancer Inst. 2017 Feb 1;109(2):1-12
89.	Bardelli A , Pantel K Liquid biopsies, what we do not know (yet) Cancer Cell. 2017 Feb 13;31(2):172-179
90.	Russo M, Bardelli A Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). pii: a029587
91.	Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A , Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur J Cancer. 2017 Jan;71:43-50
92.	Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016 Dec 8;7:13665.
93.	Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, Houppé C, Destouches D, Shchors K, Prochasson C, Mongelard F, Lamba S, Bardelli A , Bouvet P, Couvelard A, Courty J, Giraudo E, Cascone I. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016 Dec 15;76(24):7181-7193.
94.	Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A , de Braud F, Di Nicolantonio F MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer. Cancer Discov. 2016 Sep;6(9):963-71

95.	Sartore-Bianchi A, Valtorta E, Amatu A, Veronese S, Lauricella C, Bonazzina E, Siravegna G, Truini M, Bardelli A , Siena S Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. ESMO Open . 2016 Aug 4;1(4):e000079
96.	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A , Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Taberero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol . 2016 Aug;27(8):1386-422
97.	Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filicetto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Taberero J, Engelman JA, Sartore-Bianchi A, Bardelli A , Siena S, Corcoran RB, Di Nicolantonio F Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Res . 2016 Aug 1;76(15):4504-15
98.	Swanton C, Soria JC, Bardelli A , Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F. Consensus on precision medicine for metastatic cancers: A report from the MAP conference. Ann Oncol . 2016 Aug;27(8):1443-8
99.	Sanchez-Martín FJ, Bellosillo B, Gelabert M, Dalmases A, Cañadas I, Vidal J, Martínez A, Argiles G, Siravegna G, Arena S, Koefoed K, Visa L, Arpi O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Taberero J, Bardelli A , Montagut C. The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab-resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res . 2016 Jul 1;22(13):3260-7
100.	Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, Cancelliere C, Di Fiore PP, Bardelli A , Penna G, Rescigno M. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med . 2016 Jun;22(6):624-31
101.	Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A *, Marsoni S*, Siena S* (*Co-Senior authors) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol . 2016 Jun;17(6):738-46
102.	Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A , Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann Oncol . 2016 Jun;27(6):1062-7
103.	Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, In 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Liefink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A , van Rheenen J, Medema RH, Tejpar S, Bernards R. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell . 2016 Apr 7;165(2):317-330
104.	Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HC, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A , Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Nat Med . 2016 Mar;22(3):262-9
105.	Siravegna G, Bardelli A Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients Mol Oncol . 2016 Mar;10(3):475-80
106.	Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med . 2016 Feb 3;8(324):324ra14.

107.	Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A , Corcoran RB. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016 Feb;6(2):147-53
108.	Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Radrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A , Martignoni M, Davite C, Galvani A, Isacchi A, Siena S. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2016 Jan; 108(1): djv306
109.	Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Sartore Bianchi A, Li G, Siena S, Bardelli A Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer Cancer Discov. 2016 Jan;6(1):36-44
110.	Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A , Hong TS, Corcoran RB. Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov. 2015 Dec;5(12):1271-81
111.	Prahallad A, Heynen GJJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Liefink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A , Bernards R PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs Cell Reports. 2015 Sep 29;12(12):1978-85
112.	Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC and Bardelli A Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers Nat Commun. 2015 Sep 22;6:8305
113.	Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffiotti R, Venesio T, Bardelli A , Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer Ann Oncol. 2015 Sep;26(9):1994-9
114.	Montagut C, Siravegna G, Bardelli A Liquid biopsies to evaluate early therapeutic response in colorectal cancer Ann Oncol. 2015 Aug;26(8):1525-7
115.	Alizadeh AA, Aranda V, Bardelli A , Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CWM, Siu L, Snyder A, Stower H, Swanton C, Verhaak RGW, JC Zenklusen, Zuber J & Zucman-Rossi J Toward understanding and exploiting tumor heterogeneity Nat Med. 2015 Aug 6;21(8):846-53
116.	Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nat Med. 2015 Jul;21(7):795-801
117.	Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritius G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A *, Montagut C* (*Co-Senior authors) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer Clin Cancer Res. 2015 May 1;21(9):2157-66
118.	Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets Nat Commun. 2015 Apr 30;6:7002
119.	Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A , Torrance C, Elez ME, Tabernero J, Villanueva J Circulating pEGFR is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. Clin Cancer Res. 2014 Dec 15;20(24):6346-56
120.	Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A TGF- α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells Clin Cancer Res. 2014 Dec 15;20(24):6429-38

121.	Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A . Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution Cancer Discov . 2014 Nov;4(11):1269-1280
122.	Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A . Acquired resistance to EGFR-targeted therapies in colorectal cancer Mol Oncol . 2014 Sep 12;8(6):1084-1094
123.	Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Gremrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A . RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells Cell Rep . 2014 Sep 11;8(5):1475-83
124.	Siravegna G, Bardelli A . Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biology . 2014 Aug 30;15(8):449.
125.	Esposito A, Bardelli A , Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G. Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev . 2014 Jun;40(5):648-55
126.	Siravegna G, Bardelli A . Minimal residual disease in breast cancer: in blood veritas. Clin Cancer Res . 2014 May 15;20(10):2505-7
127.	Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Gremrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A †, Trusolino L, Bernards R† (†Co-Senior authors) Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 Cell Reports . 2014 Apr 10;7(1):86-93
128.	Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Gremrum W, Hofland I, Schlicker A, Wessels L, Beijersbergen RL, Bardelli A , Di Nicolantonio F, Eggermont AMM, Bernards R Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature . 2014 Apr 3;508(7494):118-22
129.	Diaz LA Jr, Bardelli A . Liquid Biopsies: Genotyping Circulating Tumor DNA J Clin Oncol . 2014 Feb 20;32(6):579-86
130.	Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A . Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Sci Transl Med . 2014 Feb 19;6(224):224ra26
131.	Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A , Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies Sci Transl Med . 2014 Feb 19;6(224):224ra24
132.	Russo M, Di Nicolantonio F, Bardelli A . Climbing RAS, the Everest of Oncogenes Cancer Discov . 2014 Jan;4(1):19-21
133.	Blair BG, Bardelli A , Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol . 2014 Jan;232(2):244-54
134.	Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A , Gallicchio M, Di Nicolantonio F. BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Mol Cancer Ther . 2013 Dec;12(12):2950-61
135.	Bottos A, Bardelli A . Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci . 2013 Nov;70(21):4131-40
136.	Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A , Di Nicolantonio F KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy Int J Cancer . 2013 Sep 1;133(5):1259-65

137.	Crowley E, Di Nicolantonio F, Loupakis F, <u>Bardelli A</u> Liquid biopsy: monitoring cancer-genetics in the blood Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
138.	<u>Bardelli A</u> , Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz Jr LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer Cancer Discov. 2013 Jun;3(6):658-7
139.	Di Nicolantonio F, <u>Bardelli A</u> Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing? Clin Cancer Res. 2013 Jun 1;19(11):2794-6
140.	Basilico C, Pennacchiotti S, Vigna E, Chiriaco C, Arena S, <u>Bardelli A</u> , Valdembrì D, Serini G, Michieli P Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET Clin Cancer Res. 2013 May 1;19(9):2381-92
141.	Martini M, Russo M, Lamba S, Vitiello E, Crowley EH, Sassi F, Romanelli D, Frattini M, Marchetti A, <u>Bardelli A</u> Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res. 2013 Mar 15;73(6):1912-21
142.	Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, <u>Bardelli A</u> Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer Nature. 2012 Jun 28;486(7404):532-6
143.	Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, <u>Bardelli A</u> , Comoglio PM, Trusolino L, Bertotti A Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res. 2012 May 1;18(9):2515-25
144.	Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, <u>Bardelli A</u> Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9
145.	<u>Bardelli A</u> , Janne PA The road to resistance: EGFR mutation and cetuximab Nat Med. 2012 Feb 6;18(2):199-200
146.	Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, <u>Bardelli A</u> , Bernards R Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature. 2012 Jan 26;483(7387):100-3
147.	Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati G, Aprile G, Giaquinta S, Torri V, <u>Bardelli A</u> , Gion M, Martoni A. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol. 2011 Nov;22(11):2424-30
148.	Martini M, Vecchione L, Siena S, Tejpar S and <u>Bardelli A</u> Targeted therapies: how personal should we go? Nat Rev Clin Oncol. 2011 Nov 15;9(2):87-97
149.	Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russoillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, <u>Bardelli A</u> † and Trusolino L† (†Co-Senior authors) A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov. 2011 Nov;1(6):508-23
150.	Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, <u>Bardelli A</u> , Tortora G Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers Clin Cancer Res. 2011 Oct 15;17(20):6531-41
151.	Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabisio O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, <u>Bardelli A</u> †, Frattini M† (†Co-Senior authors) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 2011 Jul 15;17(14):4901-14
152.	Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, <u>Bardelli A</u> , Siena S. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S1-5

153.	De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcborg JR, Simes J, Karapetis CS, <u>Bardelli A</u> *, Tejpar S* (* Shared last authorship) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA . 2010 Oct 27;304(16):1812-20.
154.	Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S and <u>Bardelli A</u> Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest . 2010 Aug;120(8):2858-6
155.	De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, <u>Bardelli A</u> , Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis Lancet Oncol . 2010 Aug;11(8):753-6
156.	Loi S, Haibe-Kains B, Majaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, <u>Bardelli A</u> , Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Proc Natl Acad Sci U S A . 2010 Jun 1;107(22):10208-13
157.	Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, <u>Bardelli A</u> , Scarpa A The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type J Exp Clin Cancer Res . 2010 Apr 16;29:32
158.	International Cancer Genome Consortium. International network of cancer genome projects. Nature . 2010 Apr 15;464(7291):993-8
159.	Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, <u>Bardelli A</u> , Van Noorden CJ The prognostic IDH1 (R132) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma. Acta Neuropathol . 2010 Apr;119(4):487-94
160.	<u>Bardelli A</u> , Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol . 2010 Mar 1;28(7):1254-61
161.	Zecchin D, <u>Bardelli A</u> Tracking the genomic evolution of breast cancer metastasis Breast Cancer Res . 2010;12(1):302
162.	Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, <u>Bardelli A</u> , Martoni AA Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) Br J Cancer . 2009 Oct 20;101(8):1261-8
163.	Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, <u>Bardelli A</u> . Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. J Natl Cancer Inst . 2009 Oct 7;101(19):1308-24
164.	Palmioli A, Sacco E, Airoidi C, Di Nicolantonio F, D'Urzo A, Shirasawa S, Sasazuki T, Di Domizio A, De Gioia L, Martegani E, <u>Bardelli A</u> , Peri F, Vanoni M. Selective cytotoxicity in cancer cells expressing K-Ras(G13D) of a bicyclic Ras inhibitor. Biochem Biophys Res Commun . 2009 Sep 4;386(4):593-7
165.	Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, <u>Bardelli A</u> *, Tamagnone L* (* Shared last authorship) Molecular Profiling of the 'Plexinome' in melanoma and pancreatic cancer Hum Mutat . 2009 Aug;30(8):1167-74
166.	Flonta SE, Arena S, Pisacane A, Michieli P and <u>Bardelli A</u> Expression and Functional Regulation of Myoglobin in Epithelial Cancers Am J Pathol . 2009 Jul;175(1):201-6
167.	Sartore-Bianchi A, Martini M, Molinari M, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M†, Siena S† and <u>Bardelli A</u> † (†Co-Senior authors) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res . 2009 Mar 1;69(5):1851-7

168.	Bleeker FE, Lamba S, Rodolfo M, Scarpa A, Leenstra S, Vandertop WP and Bardelli A Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes Hum Mutat. 2009 Feb;30(2):E451-9
169.	Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A and Bardelli A IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors Hum Mutat. 2009 Jan;30(1):7-11
170.	Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino M, Fantozzi R, Medico E and Bardelli A Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9
171.	Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol. 2008 Dec 10;26(35):5705-12
172.	Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Del Grammastro M, Sciarrotta MG, Zanon C, Marchetti A*, Bardelli A* (*Co-Senior authors) AKT1 (E17K) in human solid tumours Cell Cycle. 2008 Jun 1;7(11):1560-3
173.	Benvenuti S, Frattini M, Arena S, Zanon C, Pierotti M, and Bardelli A PIK3CA cancer mutations display gender and tissue specificity patterns Hum Mutat. 2008 Feb;29(2):284-8
174.	Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A* and Pusztai L* (* Shared last authorship) PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer Breast Cancer Res. 2008;10(2):R27
175.	Bleeker FE, Bardelli A Genomic landscapes of cancers: prospects for targeted therapies Pharmacogenomics. 2007 Dec;8(12):1629-33
176.	Arena S, Isella C, Martini M, de Marco A, Medico E and Bardelli A Knock-in of oncogenic KRAS does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers Cancer Res. 2007 Sep 15;67(18):8468-76
177.	Saletta F, Matullo G, Manuguerra M, Arena S, Bardelli A* and Vineis P (* Shared last authorship) Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells Cancer Res. 2007 Aug 1;67(15):7088-94
178.	Arena S, Pisacane A, Mazzone M, Comoglio PM and Bardelli A Genetic targeting of the kinase activity of the Met receptor in cancer cells Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11412-7
179.	Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C and Bardelli A Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma Cancer Res. 2007 Apr 15;67(8):3545-50
180.	Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, and Bardelli A Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res. 2007 Mar 15;67(6):2643-8
181.	Frattini M, Signoroni S, Pilotti S, Bertario L, Benvenuti S, Zanon C, Bardelli A , Pierotti MA Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer Cancer Res. 2005 Dec 1;65(23):11227
182.	Moroni M, Sartore-Bianchi A, Benvenuti S, Artale S, Bardelli A , and Siena S Somatic mutation of EGFR catalytic domain and treatment with Gefitinib in colorectal cancer Ann Oncol. 2005 Nov;16(11):1848-9
183.	Polato F, Codegani A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A , Brogginini M PRL-3 phosphatase is implicated in ovarian cancer growth Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9
184.	Arena S, Benvenuti S, and Bardelli A Genetic analysis of the kinome and phosphatome in cancer Cell Mol Life Sci. 2005 Sep;62(18):2092-9
185.	Parsons DW, Wang TL, Samuels Y, Bardelli A , Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C and Velculescu VE Colorectal cancer: Mutations in a signalling pathway Nature. 2005 Aug 11;436(7052):792

186.	Bachman KE, Sager J, Cheong I, Catto M, Bardelli A , Park BH, Vogelstein B, Carotti A, Kinzler KW, and Lengauer C Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells Mol Cancer Ther. 2005 Jun;4(6):1026-30
187.	Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, and Bardelli A Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol. 2005 May;6(5):279-86
188.	Bardelli A , and Velculescu VE Mutational analysis of gene families in human cancer Curr Opin Genet Dev. 2005 Feb;15(1):5-12. Review
189.	Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A , Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, and Neel BG Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Res. 2004 Dec 15;64(24):8816-20
190.	Kohli M, Yu J, Seaman C, Bardelli A , Kinzler KW, Vogelstein B, Lengauer C, and Zhang L SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16897-902
191.	Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A , Jiang Y, St Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, and Madden SL Alterations in vascular gene expression in invasive breast carcinoma Cancer Res. 2004 Nov 1;64(21):7857-66
192.	Wang Z, Shen D, Parsons DW, Bardelli A , Sager J, Szabo S, Ptak J, Silliman N, Peters BA, Van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, and Velculescu VE Mutational analysis of the tyrosine phosphatome in colorectal cancers Science. 2004 May 21;304(5674):1164-6
193.	Samuels, Y, Wang, Z, Bardelli A , Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science. 2004 Apr 23;304(5670):554
194.	Wang TL, Diaz LD, Romans K, Bardelli A , Saha S, Galizia G, Choti M, Donehower R, Parmigiani R, Shih IeM, Iacobuzio-Donahue C, Kinzler KC, Vogelstein B, Lengauer C, and Velculescu VE Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-FU in metastatic colorectal cancer patients Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94
195.	Bardelli A , Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VE, Kinzler KW, Vogelstein B PRL-3 Expression in metastatic cancers Clin Cancer Res. 2003 Nov 15;9(15):5607-15
196.	Buckhaults P, Zhang Z, Chen Y, Wang T, St. Croix B, Saha S, Bardelli A , Morin P, Polyak K, Hruban R, Velculescu V, and Shih IeM Identifying Tumor Origin Using a Gene Expression-Based Classification Map Science. 2003 May 9;300(5621):949
197.	Bardelli A , Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers Science. 2003 May 9;300(5621):949
198.	Rajagopalan H, Bardelli A , Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature. 2002 Aug 29;418(6901):934
199.	Saha S, Bardelli A , Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, and Vogelstein A A Phosphatase Associated With Metastasis of Colorectal Cancer Science. 2001 Nov 9;294(5545):1343-6
200.	Bardelli A , Cahill D, Lederer G, Speicher M, Kinzler K, Vogelstein B and Lengauer C Carcinogen-Specific Induction of Genetic Instability Proc Natl Acad Sci USA. 2001 May 8;98(10):5770-5
201.	Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A , Basilico C, Michieli P, and Comoglio PM Different Point Mutations In The MET Oncogene Elicit Distinct Biological Properties FASEB J. 2000 Feb;14(2):399-406

202.	Williams TA, Longati P, Pugliese L, Gual P, <u>Bardelli A</u> , and Michieli P MET(PRC) Mutations In The RON Receptor Result In Upregulation of Tyrosine Kinase Activity And Acquisition of Oncogenic Potential J Cell Physiol. 1999 Dec;181(3):507-14
203.	<u>Bardelli A</u> , Longati P, Williams TA, Benvenuti S, Comoglio PM A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth J Biol Chem. 1999 Oct 8;274(41):29274-81
204.	Michieli P, Basilico C, Pennacchietti S, Maffè A, Tamagnone L, Giordano S, <u>Bardelli A</u> and Comoglio PM Mutant Met-Mediated Transformation Is Ligand-Dependent And Can Be Inhibited By HGF Antagonists Oncogene. 1999 Jul 22;18(29):4275-81.
205.	Olivero M, Valente G, <u>Bardelli A</u> , Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio PM and Di Renzo MF Novel Mutation In The ATP Binding Site of The MET Oncogene Tyrosine Kinase In A HPRCC Family Int J Cancer. 1999 Aug 27;82(5):640-3
206.	Vigna E, Gramaglia D, Longati P, <u>Bardelli A</u> , and Comoglio PM Loss of The Exon Encoding The Juxtamembrane Domain Is Essential For The Oncogenic Activation of TPR-MET Oncogene. 1999 Jul 22;18(29):4275-81.
207.	<u>Bardelli A</u> , Basile ML, Audero E, Giordano S, Wennström S, Ménard S, Comoglio PM and Ponzetto C Concomitant Activation of Pathways Downstream of Grb2 and PI 3-Kinase Is Required For <i>Met</i> -Mediated Metastasis Oncogene. 1999 Feb 4;18(5):1139-46
208.	<u>Bardelli A</u> , Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari S, Michieli P, and Comoglio PM Uncoupling Signal Transducers from Oncogenic <i>MET</i> Mutants Abrogates Cell Transformation and Inhibits Invasive Growth Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14379-83
209.	Boccaccio C, Andò M, Tamagnone L, <u>Bardelli A</u> , Michieli P, Battistini C, Comoglio PM Induction of epithelial tubules by growth factor HGF depends on the STAT pathway Nature. 1998 Jan 15;391(6664):285-8
210.	<u>Bardelli A</u> , Longati P, Gramaglia D, Stella MC and Comoglio PM GAB1 Coupling To The HGF/ <i>MET</i> Receptor Multifunctional Docking Site Requires Binding of Grb2 and Correlates with the Transforming Potential Oncogene. 1997 Dec 18;15(25):3103-11
211.	Giordano S*, <u>Bardelli A</u> *, Zhen Z, Menard S, Ponzetto C and Comoglio PM (* <i>contributed equally to this work</i>) A Point Mutation In The <i>Met</i> Oncogene Abrogates Metastasis Without Affecting Transformation Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13868-72.
212.	Besser D, <u>Bardelli A</u> , Didichenko S, Thelen M, Comoglio PM, Ponzetto C, Nagamine Y Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2 Oncogene. 1997 Feb 13;14(6):705-11
213.	<u>Bardelli A</u> , Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C and Comoglio PM HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death EMBO J. 1996 Nov 15;15(22):6205-12
214.	Ponzetto C, Zhen Z, Audero E, Maina F, <u>Bardelli A</u> , Basile ML, Giordano S, Narsimhan R and Comoglio PM Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility J Biol Chem. 1996 Jun 14;271(24):14119-23
215.	Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, <u>Bardelli A</u> , Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma Mol Cell Biol. 1996 May;16(5):2151-63
216.	Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, <u>Bardelli A</u> , Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG, Comoglio PM The mitogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein Oncogene. 1995 Apr 20;10(8):1631-8
217.	Naldini L, Vigna E, <u>Bardelli A</u> , Follenzi A, Galimi F and Comoglio PM Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction J Biol Chem. 1995 Jan 13;270(2):603-11
218.	Ponzetto C, <u>Bardelli A</u> , Zhen Z, Maina F, Dalla Zonca P, Giordano S, Graziani A, Panayotou G and Comoglio PM A Multifunctional Docking Site Mediates Signalling And Transformation By The Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor Family Cell. 1994 Apr 22;77(2):261-71
219.	Longati P, <u>Bardelli A</u> , Ponzetto C, Naldini L and Comoglio PM Tyrosine1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor) Oncogene. 1994 Jan;9(1):49-57
220.	Ponzetto C, <u>Bardelli A</u> , Maina F, Longati P, Panayotou G, Dhand R, Waterfield MD and Comoglio PM A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor Mol Cell Biol. 1993 Aug;13(8):4600-8

- | | |
|------|--|
| 221. | <p><u>Bardelli A</u>, Maina F, Gout I, Fry MJ, Waterfield MD, Comoglio PM, and Ponzetto C
Autophosphorylation Promotes Complex Formation of Recombinant Hepatocyte Growth Factor Receptor With Cytoplasmic Effectors Containing SH2 Domains
Oncogene. 1992 Oct;7(10):1973-8</p> |
| 222. | <p>Naldini L, Weidner KM, Vigna E, Gaudino G, <u>Bardelli A</u>, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, Birchmeier W and Comoglio, PM
Scatter Factor And Hepatocyte Growth Factor Are Indistinguishable Ligands For The Met Receptor
EMBO J. 1991 Oct;10(10):2867-78</p> |